{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atezolizumab&page=5", "query": { "intervention": "atezolizumab", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 512, "total_pages": 52, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atezolizumab&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atezolizumab&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T14:02:06.129Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05908786", "title": "A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Hepatocellular" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Tobemstomig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2023-12-05", "completion_date": "2025-11-13", "has_results": true, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-12T14:02:06.129Z", "location_count": 5, "location_summary": "Los Angeles, California • Santa Monica, California • Washington D.C., District of Columbia + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "New York", "state": "New York" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05908786" }, { "nct_id": "NCT06109272", "title": "A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Livmoniplimab", "type": "DRUG" }, { "name": "Budigalimab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2024-01-11", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-12T14:02:06.129Z", "location_count": 13, "location_summary": "Duarte, California • Irvine, California • Orange, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Merriam", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06109272" }, { "nct_id": "NCT04432207", "title": "A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Non Small Cell Lung Cancer Stage IIIB", "Non-small Cell Lung Cancer Stage IV", "Squamous Non-small-cell Lung Cancer", "Large Cell Carcinoma Lung", "Adenocarcinoma Lung" ], "interventions": [ { "name": "IMU-201 (administered as PD1-Vaxx) - Regimen 1", "type": "BIOLOGICAL" }, { "name": "IMU-201 (administered as PD1-Vaxx) - Regimen 2", "type": "BIOLOGICAL" }, { "name": "IMU-201 (administered as PD1-Vaxx) - Regimen 3", "type": "BIOLOGICAL" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Standard of care chemotherapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Imugene Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2020-11-30", "completion_date": "2024-11-07", "has_results": false, "last_update_posted_date": "2026-03-25", "last_synced_at": "2026-10-12T14:02:06.129Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Hackensack, New Jersey • Columbus, Ohio", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04432207" }, { "nct_id": "NCT03141684", "title": "Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Alveolar Soft Part Sarcoma", "Unresectable Alveolar Soft Part Sarcoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 63, "start_date": "2017-04-25", "completion_date": "2026-10-31", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-12T14:02:06.129Z", "location_count": 42, "location_summary": "Buena Park, California • Los Angeles, California • Newport Beach, California + 28 more", "locations": [ { "city": "Buena Park", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03141684" }, { "nct_id": "NCT03533283", "title": "An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkins Lymphoma" ], "interventions": [ { "name": "Glofitamab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "89Zr-Df-IAB22M2C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 211, "start_date": "2018-05-08", "completion_date": "2026-10-16", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-12T14:02:06.129Z", "location_count": 1, "location_summary": "Charlotte, North Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03533283" }, { "nct_id": "NCT04262154", "title": "Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Prostate Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "GnRH analog", "type": "DRUG" }, { "name": "Stereotactic Body Radiotherapy (SBRT)", "type": "RADIATION" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Follow up", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 28, "start_date": "2020-03-03", "completion_date": "2026-09", "has_results": true, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-10-12T14:02:06.129Z", "location_count": 8, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04262154" }, { "nct_id": "NCT06492954", "title": "Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Osteosarcoma", "Pulmonary Recurrence of Osteosarcoma" ], "interventions": [ { "name": "Surgical Resection", "type": "PROCEDURE" }, { "name": "Stereotactic Body Radiation Therapy (SBRT)", "type": "RADIATION" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "50 Years", "sex": "ALL", "summary": "Up to 50 Years" }, "enrollment_count": 12, "start_date": "2026-10", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-12T14:02:06.129Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06492954" }, { "nct_id": "NCT03452137", "title": "A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 406, "start_date": "2018-04-03", "completion_date": "2024-03-06", "has_results": true, "last_update_posted_date": "2024-10-09", "last_synced_at": "2026-10-12T14:02:06.129Z", "location_count": 12, "location_summary": "Duarte, California • La Jolla, California • Santa Monica, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03452137" }, { "nct_id": "NCT04902040", "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Bladder Carcinoma", "Advanced Lung Non-Small Cell Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Merkel Cell Carcinoma", "Advanced Renal Cell Carcinoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III Merkel Cell Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV Merkel Cell Carcinoma AJCC v8", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage III Merkel Cell Carcinoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Merkel Cell Carcinoma AJCC v8", "Stage III Bladder Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IIIA Bladder Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Bladder Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Bladder Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Bladder Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Plinabulin", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2021-04-14", "completion_date": "2025-02-27", "has_results": true, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-10-12T14:02:06.129Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04902040" }, { "nct_id": "NCT03973333", "title": "Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Select Advanced Solid Tumors" ], "interventions": [ { "name": "IMC-C103C", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immunocore Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-05-17", "completion_date": "2023-09-25", "has_results": false, "last_update_posted_date": "2024-10-18", "last_synced_at": "2026-10-12T14:02:06.129Z", "location_count": 10, "location_summary": "Los Angeles, California • Sacramento, California • Aurora, Colorado + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03973333" } ] }